SCHEMBL735552

SCHEMBL735552

O=C1CCN(c2ccc(C(F)(F)F)cc2)CCN1[C@H](CO)CCN1CCC2(CC2)C(O)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 1/20 0.39
ADAMTS5 Q9UNA0 1/20 0.38
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ME2 P23368 1/20 0.34
ME1 P48163 1/20 0.34
ME3 Q16798 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
HTR1A P08908 5/20 0.34
DRD2 P14416 2/20 0.34
CA12 O43570 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
DRD4 P21917 1/20 0.34
HTR2A P28223 1/20 0.33
DRD3 P35462 1/20 0.33
DEGS1 O15121 1/20 0.33
ADRA1D P25100 1/20 0.33
ADRA1A P35348 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL735551 1.00 HTR7 (0.39) HTR7ADAMTS5LMNASMN1; SMN2ME2
SCHEMBL735889 0.90 HTR7 (0.45) HTR7LMNASMN1; SMN2HTR1A
SCHEMBL735916 0.90 HTR7 (0.45) HTR7LMNASMN1; SMN2HTR1A
SCHEMBL735890 0.90 HTR7 (0.45) HTR7LMNASMN1; SMN2HTR1A
SCHEMBL733506 0.90 HTR7 (0.45) HTR7LMNASMN1; SMN2HTR1A
SCHEMBL733507 0.90 HTR7 (0.45) HTR7LMNASMN1; SMN2HTR1A
SCHEMBL734982 0.89 LIPE (0.43)
SCHEMBL734983 0.89 LIPE (0.43)
SCHEMBL736362 0.85 HTR7 (0.48) HTR7LMNASMN1; SMN2HTR1ADRD2
SCHEMBL736361 0.85 HTR7 (0.48) HTR7LMNASMN1; SMN2HTR1ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US disclosed
EP-2321285-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-La Roche AG (CH) 2011-05-18 EP disclosed
WO-2010012619-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 WO disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 HTR7 408/4885ADAMTS5 4707/4885LMNA 3760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.